Excitatory Projections from the Prefrontal Cortex to Nucleus Accumbens Core D1-MSNs and κ Opioid Receptor Modulate Itch-Related Scratching Behaviors.

Xiao-Bo Wu, Qian Zhu, Ming-Hui Gao, Sheng-Xiang Yan, Pan-Yang Gu, Peng-Fei Zhang, Meng-Lin Xu, Yong-Jing Gao
Author Information
  1. Xiao-Bo Wu: Institute of Pain Medicine and Special Environmental Medicine, Co-innovation Center of Neuroregeneration, Nantong University, Jiangsu 226019, China gaoyongjing@ntu.edu.cn xbwu1983@ntu.edu.cn.
  2. Qian Zhu: Institute of Pain Medicine and Special Environmental Medicine, Co-innovation Center of Neuroregeneration, Nantong University, Jiangsu 226019, China.
  3. Ming-Hui Gao: Institute of Pain Medicine and Special Environmental Medicine, Co-innovation Center of Neuroregeneration, Nantong University, Jiangsu 226019, China.
  4. Sheng-Xiang Yan: Institute of Pain Medicine and Special Environmental Medicine, Co-innovation Center of Neuroregeneration, Nantong University, Jiangsu 226019, China.
  5. Pan-Yang Gu: Institute of Pain Medicine and Special Environmental Medicine, Co-innovation Center of Neuroregeneration, Nantong University, Jiangsu 226019, China.
  6. Peng-Fei Zhang: Institute of Pain Medicine and Special Environmental Medicine, Co-innovation Center of Neuroregeneration, Nantong University, Jiangsu 226019, China.
  7. Meng-Lin Xu: Institute of Pain Medicine and Special Environmental Medicine, Co-innovation Center of Neuroregeneration, Nantong University, Jiangsu 226019, China.
  8. Yong-Jing Gao: Institute of Pain Medicine and Special Environmental Medicine, Co-innovation Center of Neuroregeneration, Nantong University, Jiangsu 226019, China gaoyongjing@ntu.edu.cn xbwu1983@ntu.edu.cn. ORCID

Abstract

Itch is an uncomfortable and complex sensation that elicits the desire to scratch. The nucleus accumbens (NAc) activity is important in driving sensation, motivation, and emotion. Excitatory afferents from the medial prefrontal cortex (mPFC), amygdala, and hippocampus are crucial in tuning the activity of dopamine receptor D1-expressing and D2-expressing medium spiny neurons (Drd1-MSN and Drd2-MSN) in the NAc. However, a cell-type and neural circuity-based mechanism of the NAc underlying acute itch remains unclear. We found that acute itch induced by compound 48/80 (C48/80) decreased the intrinsic membrane excitability in Drd1-MSNs, but not in Drd2-MSNs, in the NAc core of male mice. Chemogenetic activation of Drd1-MSNs alleviated C48/80-induced scratching behaviors but not itch-related anxiety-like behaviors. In addition, C48/80 enhanced the frequency of spontaneous EPSCs (sEPSCs) and reduced the paired-pulse ratio (PPR) of electrical stimulation-evoked EPSCs in Drd1-MSNs. Furthermore, C48/80 increased excitatory synaptic afferents to Drd1-MSNs from the mPFC, not from the basolateral amygdala (BLA) or ventral hippocampus (vHipp). Consistently, the intrinsic excitability of mPFC-NAc projecting pyramidal neurons was increased after C48/80 treatment. Chemogenetic inhibition of mPFC-NAc excitatory synaptic afferents relieved the scratching behaviors. Moreover, pharmacological activation of κ opioid receptor (KOR) in the NAc core suppressed C48/80-induced scratching behaviors, and the modulation of KOR activity in the NAc resulted in the changes of presynaptic excitatory inputs to Drd1-MSNs in C48/80-treated mice. Together, these results reveal the neural plasticity in synapses of NAc Drd1-MSNs from the mPFC underlying acute itch and indicate the modulatory role of the KOR in itch-related scratching behaviors. Itch stimuli cause strongly scratching desire and anxiety in patients. However, the related neural mechanisms remain largely unclear. In the present study, we demonstrated that the pruritogen compound 48/80 (C48/80) shapes the excitability of dopamine receptor D1-expressing medium spiny neurons (Drd1-MSNs) in the nucleus accumbens (NAc) core and the glutamatergic synaptic afferents from medial prefrontal cortex (mPFC) to these neurons. Chemogenetic activation of Drd1-MSNs or inhibition of mPFC-NAc excitatory synaptic afferents relieves the scratching behaviors. In addition, pharmacological activation of κ opioid receptor (KOR) in the NAc core alleviates C48/80-induced itch. Thus, targeting mPFC-NAc Drd1-MSNs or KOR may provide effective treatments for itch.

Keywords

References

  1. J Neurosci. 2018 May 2;38(18):4316-4328 [PMID: 29626166]
  2. Neuron. 2019 May 8;102(3):564-573.e6 [PMID: 30878290]
  3. Annu Rev Psychol. 2015 Jan 3;66:25-52 [PMID: 25251489]
  4. Biol Psychiatry. 2015 Feb 1;77(3):212-222 [PMID: 25173629]
  5. Neuron. 2019 May 22;102(4):858-872.e5 [PMID: 31000426]
  6. Neurosci Bull. 2018 Feb;34(1):54-63 [PMID: 28401489]
  7. J Invest Dermatol. 2015 Feb;135(2):560-568 [PMID: 25211175]
  8. J Neurosci. 2019 Aug 14;39(33):6472-6481 [PMID: 31217328]
  9. Neurosci Biobehav Rev. 2018 Apr;87:17-26 [PMID: 29374516]
  10. Eur J Neurosci. 2010 Jan;31(1):14-28 [PMID: 20092552]
  11. Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2726-31 [PMID: 26831103]
  12. PLoS One. 2013 Dec 06;8(12):e82389 [PMID: 24324781]
  13. Nature. 2011 Jun 29;475(7356):377-80 [PMID: 21716290]
  14. Brain. 2014 Feb;137(Pt 2):313-22 [PMID: 23794605]
  15. Biol Psychiatry. 2020 Jun 1;87(11):954-966 [PMID: 31924324]
  16. Neuron. 2017 Jan 04;93(1):147-163 [PMID: 28056342]
  17. Biol Psychiatry. 2012 Jun 15;71(12):1061-7 [PMID: 22196983]
  18. Neuropsychopharmacology. 2018 Oct;43(11):2320-2330 [PMID: 29993042]
  19. Neuron. 2012 Jun 7;74(5):858-73 [PMID: 22681690]
  20. Neurosci Biobehav Rev. 2016 Sep;68:370-386 [PMID: 27235078]
  21. J Neurosci. 2015 Apr 1;35(13):5247-59 [PMID: 25834050]
  22. J Neurosci. 2021 Jan 13;41(2):354-365 [PMID: 33219004]
  23. Neuropsychopharmacology. 2016 Mar;41(4):989-1002 [PMID: 26239494]
  24. J Neurosci. 2018 Apr 11;38(15):3823-3839 [PMID: 29540548]
  25. Neuropsychopharmacology. 2022 Mar;47(4):891-901 [PMID: 34564712]
  26. Elife. 2021 May 25;10: [PMID: 34032210]
  27. Nat Neurosci. 2012 Feb 12;15(4):613-9 [PMID: 22327472]
  28. J Neurophysiol. 2001 Mar;85(3):1153-8 [PMID: 11247984]
  29. Nat Neurosci. 2015 Oct;18(10):1394-404 [PMID: 26404714]
  30. J Neurosci. 2018 Nov 14;38(46):9856-9869 [PMID: 30266741]
  31. J Neurosci. 2009 May 6;29(18):5820-31 [PMID: 19420249]
  32. Neuroscience. 1992 Oct;50(4):751-67 [PMID: 1448200]
  33. Int J Neuropsychopharmacol. 2016 Apr 29;19(5): [PMID: 26625893]
  34. Biol Psychiatry. 2013 Oct 1;74(7):520-8 [PMID: 23751206]
  35. Neuropharmacology. 2020 Dec 15;181:108341 [PMID: 33011200]
  36. Neurosci Bull. 2022 Dec 17;: [PMID: 36528690]
  37. Annu Rev Neurosci. 2009;32:127-47 [PMID: 19400717]
  38. Science. 2013 Sep 27;341(6153):1521-5 [PMID: 24072923]
  39. Science. 2014 Aug 1;345(6196):535-42 [PMID: 25082697]
  40. Front Cell Neurosci. 2018 Aug 13;12:240 [PMID: 30150924]
  41. J Neurosci. 2012 Jul 4;32(27):9124-32 [PMID: 22764222]
  42. Nature. 2018 Dec;564(7735):258-262 [PMID: 30478293]
  43. J Comp Neurol. 2002 Sep 2;450(4):345-65 [PMID: 12209848]
  44. Int J Mol Sci. 2016 Mar 22;17(3):425 [PMID: 27011178]
  45. Cell Rep. 2018 Apr 17;23(3):866-877 [PMID: 29669290]
  46. Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):32155-32164 [PMID: 33257584]
  47. Nat Commun. 2020 Jun 16;11(1):3052 [PMID: 32546780]
  48. Neuron. 2018 Jan 17;97(2):434-449.e4 [PMID: 29307710]
  49. Nat Neurosci. 2016 Feb;19(2):220-2 [PMID: 26691834]
  50. J Neurophysiol. 2014 Feb;111(3):488-98 [PMID: 24155004]
  51. J Neurosci. 2019 Apr 24;39(17):3345-3356 [PMID: 30819800]
  52. Neurosci Bull. 2021 Sep;37(9):1345-1350 [PMID: 34057697]
  53. Behav Brain Res. 2021 Aug 6;411:113388 [PMID: 34052263]
  54. Acta Derm Venereol. 2012 Sep;92(5):555-60 [PMID: 22504709]
  55. Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):713-8 [PMID: 23267100]
  56. Eur J Pain. 2016 Jan;20(1):8-13 [PMID: 26417885]
  57. Biol Psychiatry. 2011 Feb 1;69(3):228-35 [PMID: 21030009]
  58. Neuropsychopharmacology. 2016 Aug;41(9):2263-74 [PMID: 26860203]
  59. Nat Commun. 2015 May 08;6:7062 [PMID: 25952660]
  60. J Invest Dermatol. 2015 Nov;135(11):2814-2823 [PMID: 26076316]
  61. J Am Soc Nephrol. 2005 Dec;16(12):3742-7 [PMID: 16251241]
  62. Allergol Int. 2010 Dec;59(4):345-54 [PMID: 20864795]
  63. Neuropsychopharmacology. 1996 Jul;15(1):87-97 [PMID: 8797195]
  64. Neuron. 2012 Nov 21;76(4):790-803 [PMID: 23177963]
  65. Sci Signal. 2016 Nov 29;9(456):ra117 [PMID: 27899527]
  66. Front Cell Neurosci. 2017 May 26;11:146 [PMID: 28603489]
  67. J Neurosci. 2011 Jan 5;31(1):126-32 [PMID: 21209197]
  68. Acta Derm Venereol. 2012 Sep;92(5):508-14 [PMID: 22002738]
  69. Eur J Pharmacol. 1995 Mar 14;275(3):229-33 [PMID: 7539379]
  70. Physiol Rev. 2017 Oct 1;97(4):1431-1468 [PMID: 28904001]

MeSH Term

Mice
Male
Animals
Nucleus Accumbens
Receptors, Opioid, kappa
Hippocampus
Neurons
Receptors, Dopamine D1
Prefrontal Cortex

Chemicals

Receptors, Opioid, kappa
Receptors, Dopamine D1

Word Cloud

Created with Highcharts 10.0.0NAcDrd1-MSNsreceptoritchscratchingbehaviorsafferentsC48/80KORmPFCneuronscoreactivationexcitatorysynapticmPFC-NAcκnucleusaccumbensactivitymedialprefrontalcortexdopamineneuralacuteexcitabilityChemogeneticC48/80-inducedopioidItchsensationdesireExcitatoryamygdalahippocampusD1-expressingmediumspinyHoweverunderlyingunclearcompound48/80intrinsicmiceitch-relatedadditionEPSCsincreasedinhibitionpharmacologicaluncomfortablecomplexelicitsscratchimportantdrivingmotivationemotioncrucialtuningD2-expressingDrd1-MSNDrd2-MSNcell-typecircuity-basedmechanismremainsfoundinduceddecreasedmembraneDrd2-MSNsmalealleviatedanxiety-likeenhancedfrequencyspontaneoussEPSCsreducedpaired-pulseratioPPRelectricalstimulation-evokedFurthermorebasolateralBLAventralvHippConsistentlyprojectingpyramidaltreatmentrelievedMoreoversuppressedmodulationresultedchangespresynapticinputsC48/80-treatedTogetherresultsrevealplasticitysynapsesindicatemodulatoryrolestimulicausestronglyanxietypatientsrelatedmechanismsremainlargelypresentstudydemonstratedpruritogenshapesglutamatergicrelievesalleviatesThustargetingmayprovideeffectivetreatmentsProjectionsPrefrontalCortexNucleusAccumbensCoreD1-MSNsOpioidReceptorModulateItch-RelatedScratchingBehaviorsD1

Similar Articles

Cited By